Delta-Fly Pharma Inc.: Update on the R&D status of DFP-10917 and DFP-14927, a novel PEG Drug Conjugate, in the patients with R/R AML

05 Jan 2024
www.businesswire.com
Phase 1ADCPhase 3Phase 2
TOKUSHIMA, Japan--(BUSINESS WIRE)--Following the previous information on June 30th in 2023, we are excited to share our latest development status.
A Phase III study of DFP-10917 in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US is undergoing of the interim analysis.
A Phase I/II study of DFP-10917 in the combination with Venetoclax (VTX) in patients with R/R AML in the U.S. is in preparation.
A patent has been granted in the U.S. for the combination therapy of DFP-10917 and VTX based on the animal study’s data by using of animal model of AML in addition to Japan and Taiwan.
Pharmacology studies of DFP-14927, which is a 4 arm PEG conjugate of DFP-10917 by amido bond, can be selectively activated by the amidase activity of protease highly expressed in the tumor, is ongoing at a major university in the US for a Phase I/II study of DFP-14927 in the patients with R/R AML.
A Phase I study of DFP-14927 in the patients with advanced solid cancers in the US has been completed with an extraordinary safe profile and also long stable diseases over 5 months in the three patients in advance for the next expansion study, which likes early Phase II study. The PK profile of DFP-10917 (active form) in the tumors of the cancer patients treated with DFP-14927 is under investigation for establishing of the good relationship with efficacy to confirm a useful drug delivery system likes ADC (antibody-drug conjugate).
Both the patents of PEGylated VTX and DFP-14927 have been granted in worldwide, and their pharmacological data have been published in the leading oncology journals.
Please find out the innovation for the miserable cancer patients by Delta-Fly Pharma Inc. and contact with us.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.